IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen
This study has been completed.
Sponsor:
VA Office of Research and Development
Information provided by:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT00018343
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: December 2004
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.
| Condition | Intervention | Phase |
|---|---|---|
| Alzheimer's Disease | Drug: estrogen | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen |
Resource links provided by NLM:
Genetics Home Reference related topics:
Alzheimer disease
MedlinePlus related topics:
Alzheimer's Disease
U.S. FDA Resources
Further study details as provided by VA Office of Research and Development:
Eligibility| Ages Eligible for Study: | 50 Years to 90 Years (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
- Post menopausal women with alzheimer's disease
- free of any major medical or neurological disease,
- medically safe to be treated with estrogen.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00018343
Please refer to this study by its ClinicalTrials.gov identifier: NCT00018343
Locations
| United States, Washington | |
| VA Puget Sound Health Care System | |
| Lakewood, Washington, United States, 98493-5000 | |
Sponsors and Collaborators
VA Office of Research and Development
Investigators
| OverallOfficial: | Suzanne Craft, Ph.D | |
| OverallOfficial: | Laura Baker, Ph.D | |
| OverallOfficial: | Murray Raskind, M.D. |
More Information
| ClinicalTrials.gov Identifier: | NCT00018343 History of Changes |
| Other Study ID Numbers: |
AGCG-007-97F |
| Study First Received: | July 3, 2001 |
| Last Updated: | January 20, 2009 |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases |
Neurocognitive Disorders Mental Disorders Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 23, 2017